{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:15:58Z","timestamp":1787796958586,"version":"build-2784847793"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Arcutis Biotherapeutics, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40257-022-00741-9","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T14:31:28Z","timestamp":1669300288000},"page":"315-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies"],"prefix":"10.1007","volume":"24","clinical-trial-number":[{"clinical-trial-number":"nct04279119","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03392168","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04211363","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04211389","registry":"10.18810\/clinical-trials-gov"}],"author":[{"suffix":"Jr","given":"Archie W.","family":"Thurston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Higham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"issue":"2","key":"741_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1046\/j.1087-0024.2003.09102.x","volume":"9","author":"RS Stern","year":"2004","unstructured":"Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136\u20139.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"741_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","volume":"84","author":"CA Elmets","year":"2021","unstructured":"Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84:432\u201370.","journal-title":"J Am Acad Dermatol"},{"key":"741_CR3","first-page":"504","volume":"9","author":"SR Feldman","year":"2016","unstructured":"Feldman SR, Goffe B, Rice G, Mitchell M, Kaur M, Robertson D, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benef. 2016;9:504\u201313.","journal-title":"Am Health Drug Benef."},{"key":"741_CR4","volume-title":"OTEZLA (apremilast) prescribing information","author":"Amgen Inc.","year":"2020","unstructured":"Amgen Inc. OTEZLA (apremilast) prescribing information. Thousand Oaks: Amgen Inc.; 2020."},{"issue":"3","key":"741_CR5","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jaad.2021.06.017","volume":"86","author":"S Narla","year":"2022","unstructured":"Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am Acad Dermatol. 2022;86(3):628\u201336.","journal-title":"J Am Acad Dermatol"},{"key":"741_CR6","unstructured":"Pfizer Labs. EUCRISA (crisaborole) prescribing information. New York: Pfizer Labs; 2020."},{"issue":"5","key":"741_CR7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.jaad.2018.10.054","volume":"80","author":"C Pao-Ling Lin","year":"2019","unstructured":"Pao-Ling Lin C, Gordon S, Her MJ, Rosmarin D. A retrospective study: application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor. J Am Acad Dermatol. 2019;80(5):1451\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"741_CR8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/pde.12872","volume":"33","author":"LT Zane","year":"2016","unstructured":"Zane LT, Kircik L, Call R, Tschen E, Draelos ZD, Chanda S, et al. Crisaborole topical ointment, 2% in patients ages 2 to 17 years with atopic dermatitis: a phase 1b, open-label, maximal-use systemic exposure study. Pediatr Dermatol. 2016;33(4):380\u20137.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"741_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40257-020-00510-6","volume":"21","author":"J Schlessinger","year":"2020","unstructured":"Schlessinger J, Shepard JS, Gower R, Su JC, Lynde C, Cha A, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to <24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020;21(2):275\u201384.","journal-title":"Am J Clin Dermatol"},{"key":"741_CR10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1124\/jpet.116.232819","volume":"358","author":"C Dong","year":"2016","unstructured":"Dong C, Virtucio C, Zemska O, Baltazar G, Zhou Y, Baia D, et al. Treatment of skin inflammation with benzoxaborole phosphodiesterase inhibitors: selectivity, cellular activity, and effect on cytokines associated with skin inflammation and skin architecture changes. J Pharmacol Exp Ther. 2016;358:413\u201322.","journal-title":"J Pharmacol Exp Ther"},{"key":"741_CR11","unstructured":"AstraZeneca Pharmaceuticals LP. Daliresp (roflumilast) prescribing information. Wilmington: AstraZeneca Pharmaceuticals LP; 2020."},{"key":"741_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2000073","volume":"383","author":"MG Lebwohl","year":"2020","unstructured":"Lebwohl MG, Papp KA, Stein Gold L, Gooderham MJ, Kircik LH, Draelos ZD, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383:229\u201339.","journal-title":"N Engl J Med"},{"issue":"11","key":"741_CR13","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2022.15632","volume":"328","author":"M Lebwohl","year":"2022","unstructured":"Lebwohl M, Kircik L, Moore A, Stein Gold L, Draelos Z, Godderham M, et al. Once-daily roflumilast cream in patients with chronic plaque psoriasis (DERMIS-1 and DERMIS-2): two randomized clinical trials. J Am Med Assoc. 2022;328(11):1073\u201384. https:\/\/doi.org\/10.1001\/jama.2022.15632.","journal-title":"J Am Med Assoc"},{"issue":"1","key":"741_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/0091270006294529","volume":"47","author":"TD Bethke","year":"2007","unstructured":"Bethke TD, B\u00f6hmer GM, Hermann R, Hauns B, Fux R, M\u00f6rike K, et al. Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol. 2007;47(1):26\u201336.","journal-title":"J Clin Pharmacol"},{"key":"741_CR15","unstructured":"Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review, Application Number: 022522Orig1s000. 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022522Orig1s000ClinPharmR.pdf. Accessed 25 Jun 2022."},{"issue":"1","key":"741_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5414\/CPP49051","volume":"49","author":"TD Bethke","year":"2011","unstructured":"Bethke TD, Lahu G. High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast. Int J Clin Pharmacol Ther. 2011;49(1):51\u20137.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"741_CR17","first-page":"149","volume":"37","author":"J Baye","year":"2012","unstructured":"Baye J. Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. Pharm Ther. 2012;37(3):149\u201361.","journal-title":"Pharm Ther"},{"issue":"8","key":"741_CR18","doi-asserted-by":"publisher","first-page":"734","DOI":"10.36849\/JDD.2020.5370","volume":"19","author":"KA Papp","year":"2020","unstructured":"Papp KA, Gooderham M, Droege M, Merritt C, Osborne DW, Berk DR, et al. Roflumilast cream improves signs and symptoms of plaque psoriasis: results from a phase 1\/2a randomized, controlled study. J Drugs Dermatol. 2020;19(8):734\u201340.","journal-title":"J Drugs Dermatol"},{"key":"741_CR19","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","volume":"9","author":"H Li","year":"2018","unstructured":"Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018;9:1048.","journal-title":"Front Pharmacol"},{"key":"741_CR20","first-page":"169","volume":"39","author":"SR Miselnicky","year":"1988","unstructured":"Miselnicky SR, Lichtin JL, Sakr A, Bronaugh RL. The influence of solubility, protein binding, and percutaneous absorption on reservoir formation in skin. J Soc Cosmet Chem. 1988;39:169\u201377.","journal-title":"J Soc Cosmet Chem"},{"key":"741_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000083707","volume":"18","author":"A Teichmann","year":"2005","unstructured":"Teichmann A, Jacobi U, Weigmann H-J, Sterry W, Lademann J. Reservoir function of the stratum corneum: development of an in vivo method to quantitatively determine the stratum corneum reservoir for topically applied substances. Skin Pharmacol Physiol. 2005;18:75\u201380.","journal-title":"Skin Pharmacol Physiol."},{"issue":"8","key":"741_CR22","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1208\/s12249-018-1196-8","volume":"19","author":"DW Osborne","year":"2018","unstructured":"Osborne DW, Musakhanian J. Skin penetration and permeation properties of Transcutol\u00ae-neat or diluted mixtures. AAPS PharmSciTech. 2018;19(8):3512\u201333.","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"741_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/bjd.14634","volume":"175","author":"SD Snape","year":"2016","unstructured":"Snape SD, Wigger-Alberti W, Goehring UM. A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test. Br J Dermatol. 2016;175(3):479\u201386.","journal-title":"Br J Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00741-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00741-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00741-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:39:37Z","timestamp":1677285577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00741-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["741"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00741-9","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"assertion":[{"value":"20 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Arcutis Biotherapeutics Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Archie W. Thurston Jr is an employee of Toxicology Solutions and a consultant with Arcutis Biotherapeutics, Inc. David R. Berk, David W.\u00a0Osborne, Scott Snyder, Robert C. Higham, and Patrick Burnett are employees of Arcutis Biotherapeutics, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"These studies were conducted in accordance with the ethical principles set forth in the Declaration of Helsinki and the International Council for Harmonization harmonized tripartite guideline regarding Good Clinical Practice (2016 guidance). Approval by the Investigational Review Board was obtained from each investigator\u2019s institution, and written informed consent or assent was obtained before enrollment. In the skin-level assessment from the phase I\/IIa study (Study 101), the protocol was approved by Research Review Board, Inc, Richmond Hill, ON, Canada, for all sites.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent or assent was obtained before enrollment in each of the studies included in this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data collected for these studies will be made available to others. Proposals for data requests will be reviewed and considered for sharing following approval of the indication. Information about when data availability will begin and end will be provided following approval of the indication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}